Response-specific antiestrogen resistance in a newly characterized MCF-7 human breast cancer cell line resulting from long-term exposure to trans-hydroxytamoxifen

Journal of Steroid Biochemistry and Molecular Biology

Volumn 59, Issue 2, 1996, Pages 121-134

  Herman, Mary E ^a   Katzenellenbogen, Benita S ^a  

^a UNIVERSITY OF ILLINOIS AT URBANA CHAMPAIGN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIESTROGEN; ESTRADIOL; ESTROGEN RECEPTOR; HYDROXYTAMOXIFEN; N BUTYL 11 (3,17BETA DIHYDROXYESTRA 1,3,5(10) TRIEN 7ALPHA YL) N METHYLUNDECANAMIDE; PROGESTERONE RECEPTOR; RETINOIC ACID; TRANSFORMING GROWTH FACTOR BETA1;

ARTICLE; BREAST CANCER; CELL CULTURE; CELL LINE; CONTROLLED STUDY; DRUG RESISTANCE; DRUG SENSITIVITY; GENE EXPRESSION; GROWTH INHIBITION; GROWTH STIMULATION; HUMAN; HUMAN CELL; NUCLEOTIDE SEQUENCE; PHENOTYPE; PROTEIN ANALYSIS; RECEPTOR DENSITY;

ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CELL DIVISION; CELL LINE; CHLORAMPHENICOL O-ACETYLTRANSFERASE; CLONE CELLS; DRUG RESISTANCE, NEOPLASM; ESTRADIOL; ESTROGEN ANTAGONISTS; FEMALE; GENE EXPRESSION; GENES, REPORTER; HUMANS; POLYMERASE CHAIN REACTION; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; RECEPTORS, TRANSFORMING GROWTH FACTOR BETA; RECOMBINANT PROTEINS; RNA, MESSENGER; TAMOXIFEN; TRANS-ACTIVATION (GENETICS); TRANSCRIPTION, GENETIC; TRANSFECTION; TRANSFORMING GROWTH FACTOR BETA; TUMOR CELLS, CULTURED;

EID: 0030266977     PISSN: 09600760     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-0760(96)00114-8     Document Type: Article

References (50)

1. 1. Osborne C. K., Coronado E. B. and Robinson J. P.: Human breast cancer in the athymic mouse: cytostatic effects of long-term antiestrogen therapy. Eur. Cancer Clin. Oncol. 23 (1987) 1189-1196.
2. 2. Gottardis M. M. and Jordan V. C.: Development of tamoxifen-stimulated growth of MCF-7 tumors in athymic mice after long-term antiestrogen administration. Cancer Res. 48 (1988) 5183-5187.
3. 3. Nawata H., Bronzert D. and Lippman M. E.: Isolation and characterization of a tamoxifen-resistant cell line derived from MCF-7 human breast cancer cells. Biol. Chem. 256 (1981) 5016-5021.
4. 4. Bronzert D. A., Greene G. L. and Lippman M. E.: Selection and characterization of a breast cancer cell line resistant to the antiestrogen LY 117018. Endocrinology 117 (1985) 1409-1417.
5. 5. Lykkesfeldt A. E. and Sorensen E. K.: Effect of estrogen and antiestrogens, on cell proliferation and synthesis of secreted proteins in the human breast cancer cell line MCF-7 and a tamoxifen resistant variant subline, AL-1. Acta Oncologica 31 (1992) 131-138.
6. 6. Brunner N., Frandsen T. L., Holst-Hansen C., Bei M., Thompson E. W., Wakeling A. E., Lippman M. E. and Clarke R.: MCF-7/LCC2: a 4-hydroxytamoxifen resistant human breast cancer variant that retains sensitivity to the steroidal antiestrogen ICI 182,780. Cancer Res. 53 (1993) 3229-3232.
7. 7. Katzenellenbogen B. S., Montano M., Le Goff P., Schodin D. J., Kraus W. L., Bhardwaj B. and Fujimoto N.: Antiestrogens: mechanisms and actions in target cells. J. Steroid Biochem. Molec. Biol. 53 (1995) 387-393.
8. 8. Arteaga C. L. and Osborne C. K., Growth factors as mediators of estrogen/antiestrogen action in human breast cancer cells. In Regulatory Mechanisms in Breast Cancer, ed. M. E. Lippman and R. B. Dickson. Kluwer Academic Press, Boston, 1991, pp. 289-305.
9. 9. Fontana J. A., Nervi C., Shao Z. M. and Jetten A. M.: Retinoic acid antagonism of estrogen-responsive transforming growth factor alpha and pS2 gene expression in breast carcinoma cells. Cancer Res. 52 (1992) 3938-3945.
10. 10. Sheikh M. S., Shao Z. M., Chen J.-C., Hussain A., Jetten A. M. and Fontana J. A.: Estrogen receptor-negative breast cancer cells transfected with the estrogen receptor exhibit increased RARα gene expression and sensitivity to growth inhibition by retinoic acid. J. Cell Biochem. 53 (1993) 394-404.
11. 11. Boettger-Tong H. L. and Stancel M.: Retinoic acid inhibits estrogen-induced uterine stromal and myometrial cell proliferation. Endocrinology 136 (1995) 2975-2983.
12. 12. Roberts A. B. and Sporn M. B.: Physiological actions and clinical applications of transforming growth factor β (TGF-β). Growth Factors 8 (1993) 1-9.
13. 13. Thompson A. M., Kerr D. J. and Steel C. M.: Transforming growth factor β1 is implicated in the failure of tamoxifen therapy in human breast cancer. Br. J. Cancer 63 (1991) 609-614.
14. 14. Knabbe C., Lippman M. E., Wakefield L. M., Flanders K. C., Kasid A., Derynck R. and Dickson R. B.: Evidence that transforming growth factor-β is a hormonally regulated negative growth factor in human breast cancer cells. Cell 48 (1987) 417-428.
15. 15. Knabbe C., Zugmaier C., Schmahl M., Dietel M., Lippman M. E. and Dickson R. B.: Induction of transforming growth factor P by the antiestrogens droloxifene, tamoxifen, and toremifene in MCF-7 cells. Am. J. Clin. Oncol. (CCT) 14 (Suppl. 2) (1991) S15-S20.
16. 16. Manning A. M., Williams A. C., Game S. M. and Paraskeva C.: Differential sensitivity of human colonic adenoma and carcinoma cells to transforming growth factor-β: conversion of an adenoma cell line to a tumorigenic phenotype is accompanied by a reduced response to the inhibitory effects of TGF-β. Oncogens 6 (1991) 1471-1476.
17. 17. Hirte H. W.: A quantitative colony-forming bioassay for transforming growth factor-β using a calorimetric endpoint. Proc. Am. Ass. Cancer Res. 34 (1993) 1429.
18. 18. Katzenellenbogen B. S. and Norman M. J.: Multihormonal regulation of the progesterone receptor in MCF-7 human breast cancer cells: interrelationships among insulin/insulin-like growth factor-I, serum, and estrogen. Endocrinology 126 (1990) 891-898.
19. 19. Read L. D., Greene G. L. and Katzenellenbogen B. S.: Regulation of estrogen receptor messenger ribonucleic acid and protein levels in human breast cancer cell lines by sex steroid hormones, their antagonists and growth factors. Molec. Endocr. 3 (1989) 295-304.
20. 20. Herman M. E. and Katzenellenbogen B. S.: Alterations in transforming growth factor α and β production and cell responsiveness during the progression of MCF-7 human breast cancer cells to estrogen-autonomous growth. Cancer Res. 54 (1994) 5867-5874.
21. 21. Cho H., Ng P. A. and Katzenellenbogen B. S.: Differential regulation of gene expression by estrogen in estrogen-growth-independent and -dependent MCF-7 human breast cancer cell sublines. Molec. Endocr. 5 (1991) 1323-1330.
22. 22. Newton C. R., Kalsheker N., Graham A., Powell S., Gammack A., Riley J. and Markham A. F.: Diagnosis of alpha 1-antitrypsin deficiency by enzymatic amplification of human genomic DNA and direct sequencing of polymerase chain reaction products. Nucl. Acids Res. 16 (1988) 8223-8243.
23. 23. Berthois Y., Katzenellenbogen J. A. and Katzenellenbogen B. S.: Phenol red in tissue culture media is a weak estrogen: implications concerning the study of estrogen-responsive cells in culture. Proc. Natn. Acad. Sci. U.S.A. 83 (1986) 2496-2500.
24. 24. Brown A. M. C., Jeltsch J. M., Roberts M. and Chambon P.: Activation of pS2 gene transcription is a primary response to estrogen in the human breast cancer cell line MCF-7. Proc. Natn. Acad. Sci. U.S.A. 81 (1984) 6344-6348.
25. 25. McGuire W. L., Chamness G. C. and Fuqua S. A. W.: Estrogen receptor variants in clinical breast cancer. Molec. Endocr. 5 (1991) 1571-1577.
26. 26. Miksicek R. J., Lei Y. and Wang Y.: Exon skipping gives rise to alternatively spliced forms of the estrogen receptor in breast tumor cells. Breast Cancer Res. Treat. 26 (1993) 163-174.
27. 27. Ueda H., Takenawa T., Millan J. C., Gesell M. S. and Brandes D.: The effects of retinoids on proliferative capacities and macromolecular synthesis in human breast cancer MCF-7 cells. Cancer (Phil.) 46 (1980) 2203-9709.
28. 28. Massague J.: Receptors for the TGF-β family. Cell 69 (1992) 1067-1070.
29. 29. Jordan V. C.: The control of hormone-dependent breast cancer growth - are we talking about estrogen alone?. Eur. J. Clin. Cancer Oncol. 24 (1988) 1245-1248.
30. 30. Katzenellenbogen B. S.: Antiestrogen resistance: mechanisms by which breast cancer cells undermine the effectiveness of endocrine therapy. J. Natn. Cancer Inst. 83 (1991) 1434-1435.
31. 31. Touchette N.: Tamoxifen resistance in breast cancer. J. NIH Res. 4 (1992) 67-72.
32. 32. Wolf D. M. and Jordan V. C.: The estrogen receptor from a tamoxifen stimulated MCF-7 tumor variant contains a point mutation in the ligand binding domain. Breast Cancer Res. Treat. 31 (1994) 129-138.
33. 33. McDonnell D. P., Clemm D. L., Herman T., Goldman M. E. Pike J. W.: Analysis of estrogen receptor function in vitro reveals three distinct classes of antiestrogens. Molec. Endocr. 9 (1995) 659-669.
34. 34. Katzenellenbogen J. A., O'Malley B. W. and Katzenellenbogen B. S.: Tripartite steroid hormone receptor pharmacology: interaction with multiple effector sites as a basis for the cell-and promoter-specific action of these hormones. Molec. Endocr. 10 (1996) 119-131.
35. R-1. Cancer Res. 54 (1994) 1587-1595.
36. 36. Wiseman L. R., Johnson M. D., Wakeling A. E., Lykkesfeldt A. E., May F. E. B. and Westley B. R.: Type-I IGF receptor and acquired tamoxifen resistance in oestrogen-responsive human breast cancer cells. Eur. J. Cancer 29A (1993) 2256-2264.
37. 37. Dauvois S., Danielian P. S., White R. and Parker M. G.: Antiestrogen ICI 164,384 reduces cellular estrogen receptor content by increasing its turnover. Proc. Num. Acad. Sci. U.S.A. 89 (1992) 4037-4041.
38. 38. Reese J. C. and Katzenellenbogen B. S.: Examination of the DNA-binding ability of estrogen receptor in whole cells: implications for hormone-independent transactivation and the actions of antiestrogens. Molec. Cell. Biol 12 (1992) 4531-4538.
39. 39. Howell A., DeFriend D., Robertson J., Blarney R. and Walton P.: Response to a specific antiestrogen (ICI 182780) in tamoxifen-resistant breast cancer. Lancet 345 (1995) 29-30.
40. 40. Hu X. F., Veroni M., De Luise M., Wakeling A., Sutherland R., Watts C. K. W. and Zalcberg J. R.: Circumvention of tamoxifen resistance by the pure antiestrogen ICI 182,780. Int. J. Cancer 55 (1993) 873-876.
41. 41. Osborne C. K., Coronado-Heinsohn E. B., Hilsenbeck S. G., McCue B. L., Wakeling A. E., McClelland R. A., Manning D. L. and Nicholson R. L: Comparison of the effects of a pure steroidal antiestrogen with those of tamoxifen in a model of human breast cancer. J. Nam. Cancer Inst. 87 (1995) 746-750.
42. 42. Fuqua S. A. W., Chamness G. C. and McGuire W. L.: Estrogen receptor mutations in breast cancer. J. Cell. Biochem. 51 (1993) 135-139.
43. 43. Mullick A. and Chambon P.; Characterization of the estrogen receptor in two antiestrogen-resistant cell lines, LY2 and T47D. Cancer Res. 50 (1990) 333-338.
44. 44. Jiang S. Y., Wolf D. M., Yingling J. M., Chang C. and Jordan V. C.: An estrogen receptor positive MCF-7 clone that is resistant to antiestrogens and estradiol. Molec. Cell. Endocr. 90 (1992) 77-86.
45. 45. Karnik P. S., Kulkarni S., Liu X., Budd G. T. and Bukowski R. M.: Estrogen receptor mutations in tamoxifen-resistant breast cancer. Cancer Res. 54 (1994) 349-353.
46. 46. Sheikh M. S., Shao Z. M., Li X. S., Dawson M., Jettan A. M., Wu S. L., Conley B. A., Garcia M., Rochefort H. and Fontana J. A.: Retinoic-resistant estrogen receptor-negative human breast carcinoma cells transfected with retinoic acid receptor-alpha acquire sensitivity to growth inhibition by retinoids. J. Biol. Chem. 269 (1994) 21440-21447.
47. 47. Butta A., MacLennan K., Flanders K. C., Sacks N. P. M., Smith L, McKinna A., Dowsett M., Wakefield L. M., Sporn M. B., Baum M. and Colletta A. A.: Induction of transforming growth factor β1 in human breast cancer in vivo following tamoxifen treatment. Cancer Res. 52 (1992) 4261-4264.
48. 48. Colletta A. A., Wakefield L. M., Howell F. V., Van Roozendal K. E. P., Danielpour D., Ebbs S. R., Sporn M. B. and Baum M.: Antioestrogens induce the secretion of active TGF-β from humn fetal fibroblasts. Br. J. Cancer 62 (1990) 405 409.
49. 49. Arteaga C. L., Coffey R. J. Jr., Dugger T. C., McCutchen C. M., Moses H. L. and Lyons R. M.: Growth stimulation of human breast cancer cells with anti-transforming growth factor beta antibodies: evidence for negative autocrine regulation by transforming growth factor beta. Cell Growth Diff. 1 (1990) 367-374.
50. 50. Arrick B. A., Korc M. and Derynck R.: Differential regulation of expression of three transforming growth factor beta species in human breast cancer cell lines by estradiol. Cancer Res. 50 (1990) 299-303.